Industry collaboration to improve health outcomes: AstraZeneca

Digital Health to address today’s most urgent healthcare challenges

In January 2020, AstraZeneca and Massachusetts General Hospital (MGH) began collaborating to leverage robust data and clinical best practices to create digital health solutions that address today’s most urgent healthcare challenges. Catalyzed by the COVID-19 pandemic and a shared mission to improve care for patients with chronic illness, this novel partnership focuses on creating and clinically validating patient-centric digital health solutions and establishing a new standard of care for chronic illness management outside of a clinical setting.

In the Press

Read the press coverage to find out more about the AstraZeneca and Huma collaboration.

One of the first projects under this collaboration, the Center for Innovation in Digital HealthCare (CIDH) managed two pilot studies on heart failure and asthma management, utilizing AstraZeneca’s AMAZE™ disease management platform in a real-world setting to improve patient engagement, care-team communication, and clinical outcomes while reducing healthcare costs. Through remote monitoring, AMAZE identified at-risk patients and delivers insights to the clinical care team at the point of care to improve the management of complex patient populations. The digital platform, including a patient app and clinician dashboard, is intended to speed up the adoption of evidence-based clinical practice to improve patient care and healthcare efficiency continuously.

Two Diseases, One Platform

AMAZE supported disease management for two different diseases: asthma and heart failure. Clinical trials utilizing the disease management platform kicked off in early 2021 and concluded at the end of the year following a 6-month extension.

The Asthma Study

The Asthma Study was supported through the joint efforts of the MGH Division of Pulmonary & Critical Care Medicine at MGH and Mass General for Children’s Division of Pediatric Pulmonary Medicine. The study’s principal investigators were Peter Moschovis, MD, MPH, a pediatric pulmonologist and Instructor in Medicine at Harvard Medical School, and Jehan Alladina, MD, Instructor in Medicine at Harvard Medical School. In March 2022, Dr. Alladina was featured in our Innovator Spotlight Q&A series, which you can read about here.

The Heart Failure Study

The Heart Failure Study was supported by the Cardiovascular Disease Prevention Center at MGH Corrigan Minehan Heart Center and directed by Pradeep Natarjan, MD, MSSC, Director of Preventive Cardiology at MGH, and Kaavya Paruchuri, MD, a cardiologist at MGH.

Following the successful conclusion of the Heart Failure and Asthma Studies, AstraZeneca and MGH expanded the use of AMAZE across multiple chronic disease areas, reaching patients throughout the Mass General Brigham system. In March 2022, CIDH was pleased to hear that AstraZeneca and Huma joined forces to scale innovation for digital health through the use of AMAZE. Our team at Mass General Hospital is proud to have helped develop the AMAZE disease management platform as part of our collaboration with AstraZeneca. The two companies will continue to collaborate to leverage this platform across multiple projects to improve clinical outcomes and bridge the gap between patients, clinicians, and researchers.